Checkpoint Capital L.P. Pliant Therapeutics, Inc. Transaction History
Checkpoint Capital L.P.
- $196 Billion
- Q4 2024
A detailed history of Checkpoint Capital L.P. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 535,494 shares of PLRX stock, worth $830,015. This represents 3.59% of its overall portfolio holdings.
Number of Shares
535,494
Previous 380,000
40.92%
Holding current value
$830,015
Previous $4.26 Billion
65.56%
% of portfolio
3.59%
Previous 2.11%
Shares
3 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
64.8MCall Options Held
228KPut Options Held
772K-
Deep Track Capital, LP Greenwich, CT5.97MShares$9.26 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$7.71 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$7.18 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$5 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.2MShares$4.96 Million1.61% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $75.5M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...